CF patients experience improved lung health with lumacaftor-ivacaftor but with caveats
In adolescent and adult patients with cystic fibrosis taking lumacaftor-ivacaftor (ORKAMBI), the combination drug appears to improve lung...
Can Blood Biomarkers Predict Clinical Response to Azithromycin in Cystic Fibrosis Patients?
Although azithromycin can lower pulmonary exacerbation (PEx) risk in patients with cystic fibrosis (CF), it does not help all patients....
Viral Respiratory Tract Infections in Young CF Children Usually Mild, Study Found
Viral respiratory tract infections in young children with cystic fibrosis tend to be mild and not require hospitalization, a study found....
Evaluating the Role of New Beta-Lactam Agents for Uncommon Pathogens
Stenotrophomonas maltophilia, Achromo-bacter xylosoxidans, and Burkholderia spp are relatively uncommon pathogens that are increasingly...
Screening for cystic fibrosis-related diabetes and prediabetes: Evaluating 1,5-anhydroglucitol, fruc
Researchers examined whether alternate glycemic markers—hemoglobin A1c (HbA1c), 1,5-anhydroglucitol (1,5AG), fructosamine (FA), and...
Hexoskin Smart Shirt Can Accurately Assess Respiratory Function, May Be Tool in CF, Study Shows
Using a simple shirt — a smart one — is closer to becoming a common method to measure lung function in patients with respiratory...
5,000 Expected to Attend Cystic Fibrosis Conference, NACFC 2019, in Nashville
The Western Hemisphere’s largest gathering of experts in cystic fibrosis gets underway later this month in Nashville, Tennessee — site of...
New Clinical Tool Predicts 1- and 2-Year Mortality in Cystic Fibrosis
Researchers in Canada have developed a novel clinical tool that uses patients’ overall health status and the risk for intermittent shock...
Lower airway infection prevalence changing in children with cystic fibrosis
The prevalence of lower airway infections with Pseudomonas aeruginosa, Staphylococcus aureus and Haemophilus influenzae among young...
AzurRx BioPharma Announces Promising Results from Trial Testing MS1819 for EPI in CF Patients
The investigational therapy MS1819 showed positive safety results in a Phase 2 clinical trial for the treatment of exocrine pancreatic...
